Related Experiment Video
Updated: Apr 16, 2026
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study
Dinesh Jothimani1, Mathew E Cramp2, Tim J S Cross3
1Institute of Liver Disease and Transplantation, Global Hospitals, Chennai, India.
Background:
Eighty percent (80%) of patients with Autoimmune hepatitis (AIH) respond to a combination of prednisolone and Azathioprine (AZA). Choice of treatment is limited for those who do not respond to this standard therapy. We evaluated the role of Mycophenolate mofetil (MMF) as a second line therapy in AIH.
Method:
A retrospective observational study was carried out on all patients who received MMF for AIH.
Results:
Twenty out of 117 patients with AIH received MMF due to AZA intolerance (18 patients) or refractory disease (2 patients). Median age of the study patients was 56 (18-79) years, Male, n = 3 (15%) and Female, n = 18 (85%). After a median follow-up period of 47 (5-83) months, 14 (73.6%) patients were still on MMF with biochemical remission, including 4 out of 5 patients with cirrhosis. One patient was lost to follow-up. Three patients were intolerant of MMF due to adverse events, and two had disease refractory to MMF. Both these patients with refractory disease to MMF were initially unresponsive to AZA therapy.
Conclusion:
MMF is a safe second line agent in patients with autoimmune hepatitis including those with cirrhosis.
